Interest of Light Therapy in Hematology - The PHOTO-TREAT Study

Institut de cancérologie Strasbourg Europe

Status: Enrolling

Conditions: Lymphoma; Leukemia, Myeloid, Acute

Treatments: Device: Phototherapy system CareMin650TM

Study type: Interventional

Funder types: Other

Identifiers

NCT06326268

2023-A02133-42 (Other Identifier)

2023-019

Details and patient eligibility

About

Chemo-induced mucositis is a common complication in patients treated for hematologic malignancies. They can manifest itself as a simple local irritation with erythema and inflammation but can also progress to erosions and ulcerations of the entire oral mucosa and are also responsible for an increased risk of infection in these immunocompromised patients.

The only therapies currently offered are local care and intravenous analgesics. Studies in pediatric hematology show the effectiveness of prevention and low-dose laser treatment in chemo-induced mucositis, both in terms of reducing the number of mucositis developed but also in terms of reducing the grade of mucositis. This currently results in a recommendation for the use of photobiomodulation by international bodies such as ESMO (European Society for Medical Oncology).

Full description

During this research, the investigators aim at validating the efficacy and impact of photo-biomodulation in the management of chemo-induced mucositis in hematology department of Strasbourg Cancer Institute (ICANS).

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient;
• Patients:

In induction of acute myeloblastic leukemia OR Allografts in first remission with myeloablative conditioning OR Autografts in the context of aggressive lymphoma;

• Signature of informed consent;
• Patient registered with social security.

Exclusion criteria

• Patient under guardianship or curatorship
• Pregnant and breastfeeding woman
• Allergy to polyurethanes

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Photobiomodulation

Other group

Description:

• Patients: In induction of acute myeloblastic leukemia OR Allografts in first remission with myeloablative conditioning OR Autografts in the context of aggressive lymphoma;

Treatment:

Device: Phototherapy system CareMin650TM